Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
L.M. Nieto Benito, G. Carretero, R. Rivera-Díaz, J.M. Carrascosa, E. Daudén, P. de la Cueva, A. Sahuquillo-Torralba, E. Herrera-Acosta, O. Baniandrés-Rodríguez, J.L. Lopez-Estebaranz, I. Belinchón, J. Riera-Monroig, M. Ferrán, F.J. Gómez-García, A. Mateu, L. Rodríguez, J. Vilar-Alejo, C. García-Donoso, F. Ballescá, L.-M. Velasco, R. Botella-Estrada, E. Herrera-Ceballos, D.P. Ruiz-Genao, M.A. Descalzo, I. García-Doval
10.1016/j.ad.2021.05.027
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
J.M. Carrascosa, N. Rivera, I. Garcia-Doval, G. Carretero, F. Vanaclocha, E. Daudén, F.J. Gómez-García, P. De-la-Cueva-Dobao, E. Herrera-Ceballos, I. Belinchón, M. Alsina, J.L. Sánchez-Carazo, M. Ferrán, J.L. Lopez-Estebaranz, B. Pérez-Zafrilla, M. Llamas, R. Rivera, C. Ferrándiz
10.1016/j.ad.2015.04.013